Molecular basis of drug interaction with L-type Ca2+ channels

被引:49
作者
Mitterdorfer, J
Grabner, M
Kraus, RL
Hering, S
Prinz, H
Glossmann, H
Striessnig, J
机构
[1] Inst Biochem Pharmakol, A-6020 Innsbruck, Austria
[2] Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany
关键词
calcium channel blockers; drug binding domains; dihydropyridines; ion channels; mutagenesis;
D O I
10.1023/A:1021933504909
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Different types of voltage-gated Ca2+ channels exist in the plasma membrane of electrically excitable cells. By controlling depolarization-induced Ca2+ entry into cells they serve important physiological functions, such as excitation-contraction coupling, neurotransmitter and hormone secretion, and neuronal plasticity. Their function is fine-tuned by a variety of modulators, such as enzymes and G-proteins. Block of so-called L-type Ca2+ channels by drugs is exploited as a therapeutic principle to treat cardiovascular disorders, such as hypertension. More recently, block of so-called non-L-type Ca2+ channels was found to exert therapeutic effects in the treatment of severe pain and ischemic stroke. As the subunits of different Ca2+ channel types have been cloned, the modulatory sites for enzymes, G-proteins, and drugs can now be determined using molecular engineering and heterologous expression. Here we summarize recent work that has allowed us to determine the sites of action of L-type Ca2+ channel modulators. Together with previous biochemical, electrophysiological, and drug binding data these results provide exciting insight into the molecular pharmacology of this voltage-gated Ca2+ channel family.
引用
收藏
页码:319 / 334
页数:16
相关论文
共 89 条
[1]  
[Anonymous], CALCIUM ANTAGONISM H
[2]   NITRENDIPINE BLOCK OF CARDIAC CALCIUM CHANNELS - HIGH-AFFINITY BINDING TO THE INACTIVATED STATE [J].
BEAN, BP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (20) :6388-6392
[3]  
BELLEMANN P, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2064
[4]   Extra- and intracellular action of quaternary devapamil on muscle L-type Ca2+-channels [J].
Berjukov, S ;
Aczel, S ;
Beyer, B ;
Kimball, SD ;
Dichtl, M ;
Hering, S ;
Striessnig, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (06) :1197-1202
[5]  
BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540
[6]   Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor [J].
Boer, R ;
Dichtl, M ;
Borchers, C ;
Ulrich, WR ;
Marecek, JF ;
Prestwich, GD ;
Glossmann, H ;
Striessnig, J .
BIOCHEMISTRY, 1996, 35 (05) :1387-1396
[7]   L-type calcium channels: Binding domains for dihydropyridines and benzothiazepines are located in close proximity to each other [J].
Brauns, T ;
Prinz, H ;
Kimball, SD ;
Haugland, RP ;
Striessnig, J ;
Glossmann, H .
BIOCHEMISTRY, 1997, 36 (12) :3625-3631
[8]   BENZOTHIAZEPINONE BINDING DOMAIN OF PURIFIED L-TYPE CALCIUM CHANNELS - DIRECT LABELING USING A NOVEL FLUORESCENT DILTIAZEM ANALOG [J].
BRAUNS, T ;
CAI, ZW ;
KIMBALL, SD ;
KANG, HC ;
HAUGLAND, RP ;
BERGER, W ;
BERJUKOV, S ;
HERING, S ;
GLOSSMANN, H ;
STRIESSNIG, J .
BIOCHEMISTRY, 1995, 34 (10) :3461-3469
[9]  
CASTELLANO A, 1993, J BIOL CHEM, V268, P12359
[10]   RECEPTOR-SITES FOR CA2+ CHANNEL ANTAGONISTS [J].
CATTERALL, WA ;
STRIESSNIG, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (06) :256-262